P-glycoprotein interactions

Osterberg, T., Norinder, U., Theoretical calculation and prediction of P-glycoprotein-interacting drugs using MolSurf parametrization and PLS statistics, Eur. J. Pharmaceut. Sci. 2000, 20, 295-303. 

Skovsgaard, T., Stein, W. D., Structure—activity relationships of P-glycoprotein interacting drugs kinetic characterization of their effects on ATPase activity, Biochim. Biophys. Acta... 

Balimane PV, Han YH, Chong S (2006) Current industrial practices of assessing permeability and P-glycoprotein interaction. AAPS J 8 E1-E13. 

Ejsing, T. B., Pedersen, A. D., and Linnet, K. (2005) P-glycoprotein interaction with risperidone and 9-OH-iisperidone studied in vitro, in knock-out mice and in drug-drug interaction experiments. Hum. Psychopharmacol. 20, 493-500. 

Osterberg, T. Norinder, U. Theoretical Calculation and Prediction of P-glycoprotein-Interaction Drugs Using MolSurf Parametrization and PLS Statistics. Eur. J. Pharm. Sci. 10, 295-303 (2000). 

See Balimane, P.V., et ai. Current Industrial Practices of Assessing Permeability and P-Glycoprotein Interaction. AAPS J. 2006, 8, El-El3. 

Rice, A., et al. Chemical modification of paclitaxel (Taxol) reduces P-glycoprotein interactions and increases permeation across the blood—brain barrier in vitro and in situ. J. Med. Chem. 2005, 48, 832-838. 

Etheridge, A.S., S.R. Black, P.R. Patel, J. So, and J.M. Mathews. 2007. An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal. Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents. PlantaMed. 73(8) 731-741. 

---